Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Comment by Robeyy18on Jul 17, 2020 2:00pm
157 Views
Post# 31282305

RE:Gentleman's bet on q4 results

RE:Gentleman's bet on q4 resultsBeen wondering to what extent EU GMP certification will help CC Pharma margins if at all this quarter?  Revenues were 88 million last quarter and they've also been approved for a small amount of growing capacity in Germany so it could be impactful.  Revenues should remain consistent or marginally higher in the German market seeing as pharmacies were considered esseential and patients would use more product if anything.  As for Canada, 180 million was recorded in a month where stores had no way to sell for a period of time so i could easily see that number ticking up to 190-200 million when june numbers are released.  Aph. will benefit disproportionately from its peers if Ontario sales growth is impressive.  Ill shoot for 155 million in revenues.  Cost per gram should decrease with aphria one and diamond at full capacity.  Really not sure if its a profitable quarter or not.
<< Previous
Bullboard Posts
Next >>